| References: |
GSK1278863 is a novel HIF-PHI, is a novel small molecule agent which has the ability to stimulate the HIF pathway and therefore, it is under investigation for treatment of anemia associated with chronic kidney disease. GSK1278863 is an investigative drug under investigation for treatment of anemia associated with chronic kidney disease. GSK1278863 is an orally administered small-molecule PHI, stabilizes HIF, which is known to modulate HIF-controlled gene products including EPO. GSK1278863 induced an effective EPO response and stimulated non-EPO mechanisms for erythropoiesis in anemic non-dialysis-dependent and dialysis-dependent patients with CKD.GSK1278863 is an orally-active small molecule agent that inhibits hypoxia-inducible factor (HIF) prolyl-4-hydroxylases (PHDs) that is currently in clinical development for the treatment of anemia associated with chronic kidney disease (CKD).For the detailed information of Daprodustat(GSK1278863), the solubility of Daprodustat(GSK1278863) in water, the solubility of Daprodustat(GSK1278863) in DMSO, the solubility of Daprodustat(GSK1278863) in PBS buffer, the animal experiment (test) of Daprodustat(GSK1278863), the cell expriment (test) of Daprodustat(GSK1278863), the in vivo, in vitro and clinical trial test of Daprodustat(GSK1278863), the EC50, IC50,and affinity,of Daprodustat(GSK1278863), For the detailed information of Daprodustat(GSK1278863), the solubility of Daprodustat(GSK1278863) in water, the solubility of Daprodustat(GSK1278863) in DMSO, the solubility of Daprodustat(GSK1278863) in PBS buffer, the animal experiment (test) of Daprodustat(GSK1278863), the cell expriment (test) of Daprodustat(GSK1278863), the in vivo, in vitro and clinical trial test of Daprodustat(GSK1278863), the EC50, IC50,and affinity,of Daprodustat(GSK1278863), Please contact DC Chemicals. |
